Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Glucagon action: New twists for an old peptide
Presenter: David A D'Alessio, MD (Duke University School of Medicine)
No relevant financial relationships

Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Chair
Presenter: Rohit Kulkarni, MD,PhD (Joslin Diabetes Center)
Relationship: Commercial Interest(s)
  Advisory Board Member: Novo Nordisk.
  Grant Recipient: Inversago.
  Grant Recipient: Insulet Corporation, Tandem Diabetes Care, Medtronic Minimed, Abbott Laboratories.

Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Chair
Presenter: Mehboob Hussain, MD (University of Michigan)
Relationship: Commercial Interest(s)
  Advisory Board Member: Novo Nordisk.
  Grant Recipient: Inversago.
  Grant Recipient: Biomarin.

Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Dual Incretin Receptor Agonists: How Far Have We Gone with “‘Twincretins”?
Presenter: Julio Rosenstock, MD (Dallas Diabetes Research Center)
Relationship: Commercial Interest(s)
  Advisory Board Member: Boehringer Ingelheim, Eli Lilly & Company, Intarcia, Janssen Research & Development Company, Novo Nordisk, Sanofi, Applied Therapeutics, Inc., Oramed, Hanmi, Associate Editor of Diabetes Care.
  Consulting Fee: Boehringer Ingelheim, Eli Lilly & Company, Intarcia, Janssen Research & Development Company, Novo Nordisk, Sanofi, Applied Therapeutics, Inc., Oramed, Hanmi, Inc., Associate Editor of Diabetes Care.
  Grant Recipient: Applied Therapeutics, Inc., Boehringer Ingelheim, Eli Lilly & Company, Genentech, Inc., Hanmi, Janssen Research & Development Company, Metacrine, Novartis Pharmaceuticals, Novo Nordisk, Oramed, Pfizer, Inc., REMD Biotherapeutics Inc., Sanofi, VTV Therapeutics. Research Investigator

Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Triple Incretin Agonists: Ready for Prime Time?
Presenter: Shweta Urva, PhD (Eli Lilly & Company)
Relationship: Commercial Interest(s)
  Employee: Eli Lilly & Company
  Stock Owner: Eli Lilly & Company
  Grant Recipient: Other (fill in the blank below)
  Grant Recipient: Employee and Shareholder only-

GIP receptor signalling in oligodendrocytes
Presenter: Clemence Blouet, PhD (University of Cambridge)
Relationship: Commercial Interest(s)
  Grant Recipient: Lilly USA, LLC, $250,000.
  Stock Owner: Eli Lilly & Company.
  Grant Recipient: Applied Therapeutics, Inc., Boehringer Ingelheim, Eli Lilly & Company, Genentech, Inc., Hanmi, Janssen Research & Development Company, Metacrine, Novartis Pharmaceuticals, Novo Nordisk, Oramed, Pfizer, Inc., REMD Biotherapeutics Inc., Sanofi, VTV Therapeutics. Research Investigator